{"organizations": [], "uuid": "dfb3d206cd4745e4c4df34312137a59d7dd0f2c0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-cardiome-announces-expanded-label/brief-cardiome-announces-expanded-label-for-aggrastat-in-china-idUSFWN1PI0TI", "country": "US", "domain_rank": 408, "title": "BRIEF-Cardiome Announces Expanded Label For Aggrastat In China", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-23T15:38:00.000+02:00", "replies_count": 0, "uuid": "dfb3d206cd4745e4c4df34312137a59d7dd0f2c0"}, "author": "", "url": "https://www.reuters.com/article/brief-cardiome-announces-expanded-label/brief-cardiome-announces-expanded-label-for-aggrastat-in-china-idUSFWN1PI0TI", "ord_in_thread": 0, "title": "BRIEF-Cardiome Announces Expanded Label For Aggrastat In China", "locations": [], "entities": {"persons": [], "locations": [{"name": "china", "sentiment": "none"}], "organizations": [{"name": "brief-cardiome announces expanded label for aggrastat in china reute", "sentiment": "negative"}, {"name": "cardiome pharma corp", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 39 PM / Updated 11 minutes ago BRIEF-Cardiome Announces Expanded Label For Aggrastat In China Reuters Staff 1 Min Read \nJan 23 (Reuters) - Cardiome Pharma Corp: \n* CARDIOME ANNOUNCES EXPANDED LABEL FOR AGGRASTATÂ® IN CHINA INCLUDING NEW STEMI INDICATION AND HIGH DOSE BOLUS REGIMEN \n* CARDIOME PHARMA - AGGRASTAT EXPANDED LABEL NOW INCLUDE PATIENTS WITH STEMI WHO ARE INTENDED FOR PRIMARY PERCUTANEOUS CORONARY INTERVENTION \n* CARDIOME PHARMA - CHINESE CENTER FOR DRUG EVALUATION ALSO APPROVED AGGRASTAT HIGH DOSE BOLUS REGIMEN TO BE USED ON BOTH INDICATED PATIENT POPULATIONS IN STUDY Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-23T15:38:00.000+02:00", "crawled": "2018-01-23T16:00:05.000+02:00", "highlightTitle": ""}